Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

HC Wainwright & Co. Reinstates Buy on Aldeyra Therapeutics, Announces $10 Price Target

Author: Benzinga Newsdesk | April 02, 2024 08:43am
HC Wainwright & Co. analyst Matthew Caufield reinstates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and announces $10 price target.

Posted In: ALDX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist